Vanguard Group Inc. Buys 10,579 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP)

Vanguard Group Inc. grew its stake in shares of CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 0.6% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,735,998 shares of the company's stock after acquiring an additional 10,579 shares during the quarter. Vanguard Group Inc. owned about 2.03% of CRISPR Therapeutics worth $68,329,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently modified their holdings of the company. Wilmington Savings Fund Society FSB acquired a new position in CRISPR Therapeutics during the third quarter worth approximately $40,000. Highline Wealth Partners LLC acquired a new stake in shares of CRISPR Therapeutics during the 4th quarter worth $39,000. Western Pacific Wealth Management LP raised its position in shares of CRISPR Therapeutics by 100.0% in the 4th quarter. Western Pacific Wealth Management LP now owns 1,000 shares of the company's stock worth $39,000 after buying an additional 500 shares during the period. Spire Wealth Management boosted its holdings in CRISPR Therapeutics by 303.7% in the fourth quarter. Spire Wealth Management now owns 1,970 shares of the company's stock valued at $78,000 after acquiring an additional 1,482 shares during the last quarter. Finally, MCF Advisors LLC acquired a new stake in CRISPR Therapeutics during the fourth quarter worth about $80,000. Institutional investors and hedge funds own 69.20% of the company's stock.

CRISPR Therapeutics Trading Down 1.2 %

NASDAQ:CRSP traded down $0.49 during trading hours on Monday, hitting $38.81. 2,625,016 shares of the stock traded hands, compared to its average volume of 1,628,924. The firm has a market cap of $3.33 billion, a price-to-earnings ratio of -8.88 and a beta of 1.85. CRISPR Therapeutics AG has a fifty-two week low of $30.04 and a fifty-two week high of $67.88. The firm has a 50 day moving average price of $41.14 and a 200 day moving average price of $44.01.

Remove Ads

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last posted its quarterly earnings results on Tuesday, February 11th. The company reported ($0.44) EPS for the quarter, beating the consensus estimate of ($1.15) by $0.71. CRISPR Therapeutics had a negative net margin of 981.54% and a negative return on equity of 18.46%. Research analysts predict that CRISPR Therapeutics AG will post -5.16 EPS for the current year.

Analyst Upgrades and Downgrades

Several research analysts recently commented on the stock. Citigroup cut their price target on shares of CRISPR Therapeutics from $89.00 to $82.00 and set a "buy" rating on the stock in a report on Tuesday, February 18th. StockNews.com raised shares of CRISPR Therapeutics to a "sell" rating in a report on Friday, March 21st. Cantor Fitzgerald reiterated a "neutral" rating on shares of CRISPR Therapeutics in a report on Wednesday, February 19th. Chardan Capital lowered their price objective on shares of CRISPR Therapeutics from $94.00 to $84.00 and set a "buy" rating for the company in a research report on Thursday, February 13th. Finally, JMP Securities reiterated a "market outperform" rating and issued a $86.00 target price on shares of CRISPR Therapeutics in a research note on Thursday, February 13th. Two investment analysts have rated the stock with a sell rating, nine have given a hold rating and eleven have assigned a buy rating to the stock. According to MarketBeat, CRISPR Therapeutics has an average rating of "Hold" and a consensus target price of $73.11.

Insider Buying and Selling at CRISPR Therapeutics

In related news, COO Julianne Bruno sold 1,198 shares of the business's stock in a transaction that occurred on Tuesday, March 11th. The stock was sold at an average price of $42.42, for a total value of $50,819.16. Following the completion of the sale, the chief operating officer now directly owns 8,263 shares in the company, valued at approximately $350,516.46. The trade was a 12.66 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Samarth Kulkarni sold 9,973 shares of the firm's stock in a transaction on Tuesday, March 11th. The shares were sold at an average price of $42.42, for a total transaction of $423,054.66. Following the completion of the transaction, the chief executive officer now owns 180,890 shares in the company, valued at $7,673,353.80. The trade was a 5.23 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 32,381 shares of company stock worth $1,608,243 over the last ninety days. 4.10% of the stock is currently owned by insiders.

CRISPR Therapeutics Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.